Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon

Zaher K OtrockRami A MahfouzZahera FahedFadi S FarhatAzzam ZiadeFadi NasrNader KassemMiguel R Abboud

PMID: 22961257

DOI: 10.1007/s12185-012-1168-9

No abstract available